Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following aromatase inhibitors, with or without CDK4/6 inhibitors. However, clinical data suggests CDK4/6 treatment may reduce re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, de Bruin, Elza C., Barry, Simon T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404292/
https://www.ncbi.nlm.nih.gov/pubmed/37543694
http://dx.doi.org/10.1038/s41523-023-00571-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404292/
https://www.ncbi.nlm.nih.gov/pubmed/37543694
http://dx.doi.org/10.1038/s41523-023-00571-w

Ejemplares similares